2024
Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
2018
Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility
Huntington S, Zhu W, Hoag J, Wang R, Zeidan A, Giri S, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A. Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility. Blood 2018, 132: 3538. DOI: 10.1182/blood-2018-99-115140.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaConsensus guidelinesFollicular lymphomaPET scansClinical utilityMedicare beneficiariesSetting of CLLEnd Results-Medicare dataPopulation-based cohort studyLarge B-cell lymphomaLow-value imagingLymphoma-directed therapyFirst-line therapyPatients' sociodemographic characteristicsElixhauser Comorbidity IndexPositron emission tomography useYears of treatmentLow clinical utilityLymphoma settingPet ownershipB-cell lymphomaHierarchical multivariable modelUse of PETTreating oncologistComorbidity index